Eric Fritz

Eric Fritz is a Partner at MVM Partners LLP, a healthcare-dedicated venture capital firm founded in 1997 with offices in Boston, London, and the San Francisco Bay Area. He joined MVM in 2019 and is based in the firm's Boston office, where he focuses on healthcare investment opportunities, particularly in medical technology.

Before joining MVM, Fritz was at McKinsey & Company, where he started as an Associate and rose to Engagement Manager. There he advised pharmaceutical and medical-device clients on corporate strategy and transactions — experience that maps directly onto MVM's deal-oriented, healthcare-specialist investing model.

Fritz's training is scientific. He earned a Ph.D. in Biological Sciences from The Rockefeller University, where his thesis research applied genomic techniques to problems in immunology, and an A.B. in Chemistry, awarded summa cum laude, from Harvard University. This combination of bench-science depth and management-consulting commercial experience underpins his work evaluating clinical and commercial-stage healthcare companies.

At MVM, Fritz takes active board roles in portfolio companies, currently serving as a director of Providence Medical Technology, Inc. (cervical spine fusion) and CurvaFix, Inc. (orthopedic trauma implants).

• Invests exclusively in healthcare: medtech/medical devices, pharma, biotech, diagnostics, life science tools, pharma services, and digital health.
• Backs companies across the lifecycle — from early-stage private companies to those in late-stage clinical development, commercialization, or already publicly listed — rather than focusing on a single stage.
• Writes large, concentrated checks (roughly $30M–$60M per company in MVM VI, with room for more), reflecting a growth/expansion-capital posture rather than seed/angel-sized investments.
• Looks for companies addressing large, undertreated clinical segments with clear benefit to patients, physicians, and health systems. On CurvaFix, Fritz said its "ability to benefit patients, physicians, and health systems, while simultaneously addressing the undertreated FFP [fragility fractures of the pelvis] segment makes CurvaFix a rare asset in the crowded world of orthopedics."
• Brings operational/board-level engagement, taking director seats and supporting commercialization — a fit for founders who want a hands-on, healthcare-specialist investor.